Hepion Pharmaceuticals (HEPA) Short Interest Ratio & Short Volume $0.08 +0.02 (+25.59%) As of 09:30 AM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Hepion Pharmaceuticals Short Interest DataHepion Pharmaceuticals (HEPA) has a short interest of 8,200 shares, representing 0.12% of the float (the number of shares available for trading by the public). This marks a -49.38% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 87,311 shares to cover all short positions.Current Short Interest8,200 sharesPrevious Short Interest16,200 sharesChange Vs. Previous Month-49.38%Dollar Volume Sold Short$344.40Short Interest Ratio0.0 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares11,435,000 sharesShort Percent of Float0.12%Today's Trading Volume2,505 sharesAverage Trading Volume87,311 sharesToday's Volume Vs. Average3% Short Selling Hepion Pharmaceuticals? Sign up to receive the latest short interest report for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartHEPA Short Interest Over TimeHEPA Days to Cover Over TimeHEPA Percentage of Float Shorted Over Time Hepion Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/20258,200 shares $344.40 -49.4%0.1%0 $0.04 7/15/202516,200 shares $782.46 -56.8%N/A0.1 $0.05 6/30/202537,500 shares $3 thousand +88.4%0.6%0.3 $0.08 6/15/202519,900 shares $1.39 thousand +42.1%0.3%0.1 $0.07 5/31/202514,000 shares $910.00 -87.4%0.2%0 $0.07 5/15/2025110,900 shares $14.03 thousand -75.3%N/A0 $0.13 4/30/2025448,200 shares $129.71 thousand -30.8%4.1%0.1 $0.29 4/15/2025647,400 shares $226.59 thousand +224.0%5.9%0.2 $0.35 3/31/2025199,800 shares $85.89 thousand +25.2%26.1%0.1 $0.43 3/15/2025159,600 shares $183.54 thousand -96.2%14.9%0.2 $1.15 Get the Latest News and Ratings for HEPA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/28/20254,160,000 shares $524.16 thousand -12.4%39.4%0.2 $0.13 2/15/20254,750,000 shares $869.73 thousand +75.3%44.9%0.3 $0.18 1/31/20252,710,000 shares $486.45 thousand +1,180.7%25.5%0.2 $0.18 1/15/2025211,600 shares $90.50 thousand +774.4%3.0%0 $0.43 12/31/202424,200 shares $11.38 thousand -44.8%0.4%0.4 $0.47 12/15/202443,800 shares $25.84 thousand -7.2%0.6%1 $0.59 11/30/202447,200 shares $31.53 thousand -26.6%0.7%1.1 $0.67 11/15/202464,300 shares $43.72 thousand -2.1%0.9%1.6 $0.68 10/31/202465,700 shares $42.64 thousand +247.6%1.1%1.5 $0.65 10/15/202418,900 shares $10.76 thousand -24.7%0.3%0.4 $0.57 9/30/202425,100 shares $16.82 thousand -59.9%0.4%0.2 $0.67 9/15/202462,600 shares $46.32 thousand -17.3%1.1%0.4 $0.74 8/31/202475,700 shares $63.44 thousand -6.8%1.3%0.5 $0.84 8/15/202481,200 shares $54.79 thousand -29.5%1.4%0.5 $0.67 7/31/2024115,200 shares $90.18 thousand +852.1%2.0%0.7 $0.78 7/15/202412,100 shares $12.83 thousand -50.4%0.2%0.1 $1.06 6/30/202424,400 shares $24.89 thousand +58.4%0.5%0.7 $1.02 6/15/202415,400 shares $17.08 thousand -40.1%0.3%0.4 $1.11 5/31/202425,700 shares $32.38 thousand -21.7%0.5%0.6 $1.26 5/15/202432,800 shares $38.05 thousand -48.7%0.6%0.7 $1.16 4/30/202463,900 shares $87.22 thousand -0.2%1.2%0.9 $1.37 4/15/202464,000 shares $139.52 thousand +1.9%1.2%0.8 $2.18 3/31/202462,800 shares $156.37 thousand +11.0%1.5%0.8 $2.49 3/15/202456,600 shares $127.92 thousand -19.6%1.3%0.7 $2.26 2/29/202470,400 shares $209.09 thousand -11.0%1.6%0.8 $2.97 2/15/202479,100 shares $211.99 thousand +18.2%1.9%0.9 $2.68 1/31/202466,900 shares $127.11 thousand -17.7%1.6%0.9 $1.90 1/15/202481,300 shares $223.58 thousand -18.0%1.9%1.2 $2.75 12/31/202399,200 shares $321.41 thousand -18.5%2.3%1.5 $3.24 12/15/2023121,700 shares $484.37 thousand -61.6%2.8%1.9 $3.98This is my Christian duty (Ad)“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.Watch Jim Rickards reveal the Old Testament Wealth Code 11/30/2023317,200 shares $1.02 million -4.4%7.4%5.7 $3.22 11/15/2023331,700 shares $959.01 thousand +15.0%7.8%6.8 $2.89 10/31/2023288,500 shares $1.35 million -22.8%6.9%8.8 $4.67 10/15/2023373,700 shares $1.72 million -11.4%9.9%12.3 $4.61 9/30/2023421,900 shares $2.11 million +10.5%11.2%15.7 $4.99 9/15/2023381,700 shares $2.00 million +24.9%10.1%13.3 $5.25 8/31/2023305,700 shares $2.28 million +3.1%8.0%8.9 $7.45 8/15/2023296,600 shares $2.07 million -8.9%7.7%0.8 $6.99 7/31/2023325,700 shares $2.59 million +2.4%8.6%0.9 $7.95 7/15/2023318,000 shares $3.18 million -1.8%8.4%0.9 $9.99 6/30/2023323,800 shares $3.40 million -11.1%8.5%0.9 $10.50 6/15/2023364,100 shares $4.21 million +52.9%9.6%1 $11.57 5/31/2023238,200 shares $2.29 million +237.4%6.3%0.7 $9.60 5/15/202370,600 shares $473.02 thousand +105.8%1.9%0.2 $6.70 4/30/2023685,900 shares $477.04 thousand +6.3%0.9%3.8 $0.70 4/15/2023645,100 shares $490.28 thousand -7.7%0.9%2.6 $0.76 3/31/2023698,800 shares $542.62 thousand -2.8%0.9%1 $0.78 3/15/2023719,000 shares $540.33 thousand +0.3%0.9%1 $0.75 2/28/2023716,600 shares $625.95 thousand -13.8%0.9%1 $0.87 2/15/2023831,100 shares $706.44 thousand -8.3%1.1%1.1 $0.85 1/31/2023905,900 shares $661.13 thousand -49.1%1.2%1.2 $0.73 1/15/20231,780,000 shares $1.65 million +221.0%2.3%2.5 $0.93 12/30/2022554,600 shares $166.55 thousand +0.3%0.7%1.7 $0.30 12/15/2022553,100 shares $182.52 thousand +3.2%0.7%2.6 $0.33 11/30/2022535,800 shares $195.67 thousand -2.5%0.7%2.9 $0.37 11/15/2022549,700 shares $241.81 thousand -5.4%0.7%3.2 $0.44 10/31/2022581,200 shares $309.49 thousand -9.9%0.8%3.9 $0.53 10/15/2022645,200 shares $296.73 thousand -6.6%0.9%4.7 $0.46 9/30/2022691,000 shares $349.09 thousand -6.3%0.9%4.9 $0.51 9/15/2022737,500 shares $441.03 thousand -9.5%1.0%5.1 $0.60 8/31/2022814,700 shares $556.20 thousand -15.3%1.1%5.2 $0.68 8/15/2022961,600 shares $712.83 thousand -12.6%1.3%5.9 $0.74 7/31/20221,100,000 shares $594 thousand +21.6%1.5%5.6 $0.54 7/15/2022904,700 shares $544.09 thousand -7.7%1.2%4.6 $0.60 6/30/2022980,300 shares $561.22 thousand -7.5%1.3%4.9 $0.57 6/15/20221,060,000 shares $717.62 thousand -7.0%1.4%4.6 $0.68 5/31/20221,140,000 shares $889.31 thousand -7.3%1.5%4.8 $0.78 5/15/20221,230,000 shares $852.39 thousand -14.6%1.6%4.1 $0.69 4/30/20221,440,000 shares $1.33 million -9.4%1.9%4.6 $0.93 4/15/20221,590,000 shares $1.67 million -7.0%2.1%4.3 $1.05 3/31/20221,710,000 shares $2.21 million +8.2%2.3%4.2 $1.29 3/15/20221,580,000 shares $1.69 million -0.6%2.1%3 $1.07 2/28/20221,590,000 shares $1.75 million -5.4%2.1%2.8 $1.10 2/15/20221,680,000 shares $1.71 million -10.2%2.2%2.7 $1.02 1/31/20221,870,000 shares $1.83 million +2.2%2.5%2.6 $0.98 1/15/20221,830,000 shares $2.12 million -6.2%2.4%2.4 $1.16 12/31/20211,950,000 shares $2.22 million +2.6%2.6%2.6 $1.14 12/15/20211,900,000 shares $2.30 million +15.2%2.5%2.4 $1.21 11/30/20211,650,000 shares $2.05 million -7.8%2.2%1.5 $1.24 11/15/20211,790,000 shares $2.63 million -1.1%2.4%1.5 $1.47This is my Christian duty (Ad)“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.Watch Jim Rickards reveal the Old Testament Wealth Code 10/29/20211,810,000 shares $2.59 million -11.3%2.4%1.5 $1.43 10/15/20212,040,000 shares $3.10 million +17.9%2.7%1.6 $1.52 9/30/20211,730,000 shares $2.65 million -40.1%2.3%1.1 $1.53 9/15/20212,890,000 shares $4.60 million +61.5%3.8%1.7 $1.59 8/31/20211,790,000 shares $2.88 million -10.5%2.4%0.9 $1.61 8/13/20212,000,000 shares $2.94 million -14.5%2.6%1.1 $1.47 7/30/20212,340,000 shares $3.60 million -2.1%3.1%1.2 $1.54 7/15/20212,390,000 shares $3.80 million +64.8%3.1%1.1 $1.59 6/30/20211,450,000 shares $2.87 million -13.7%1.9%0.7 $1.98 6/15/20211,680,000 shares $3.70 million +27.3%2.2%0.8 $2.20 5/28/20211,320,000 shares $2.24 million +6.5%1.7%0.4 $1.70 5/14/20211,240,000 shares $1.93 million -32.6%N/A0.3 $1.56 4/30/20211,840,000 shares $3.28 million -20.7%N/A0.3 $1.78 4/15/20212,320,000 shares $4.08 million -22.9%N/A0.4 $1.76 3/31/20213,010,000 shares $5.36 million +57.6%N/A0.5 $1.78 3/15/20211,910,000 shares $4.66 million -26.5%N/A0.3 $2.44 2/26/20212,600,000 shares $5.10 million +273.3%N/A0.5 $1.96 2/12/2021696,500 shares $1.98 million +159.7%N/A0.1 $2.84 1/29/2021268,200 shares $549.81 thousand -6.8%N/A0.1 $2.05 1/15/2021287,600 shares $672.98 thousand -58.0%N/A0.1 $2.34 12/31/2020685,100 shares $1.61 million +236.7%N/A0.4 $2.35 12/15/2020203,500 shares $386.65 thousand -43.4%N/A0.1 $1.90 11/30/2020359,500 shares $607.56 thousand +9.7%N/A0.4 $1.69 11/15/2020327,600 shares $956.59 thousand +51.3%N/A1.5 $2.92 10/30/2020216,600 shares $723.44 thousand -39.7%N/A0.9 $3.34 10/15/2020359,400 shares $1.25 million -26.7%N/A0.9 $3.47 9/30/2020490,500 shares $1.53 million +4.1%N/A0.9 $3.11 9/15/2020471,000 shares $1.53 million -22.7%N/A0.3 $3.25 HEPA Short Interest - Frequently Asked Questions What is Hepion Pharmaceuticals' current short interest? Short interest is the volume of Hepion Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 8,200 shares of HEPA short. 0.12% of Hepion Pharmaceuticals' shares are currently sold short. Learn More on Hepion Pharmaceuticals' current short interest. What is a good short interest percentage for Hepion Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.12% of Hepion Pharmaceuticals' floating shares are currently sold short. Is Hepion Pharmaceuticals' short interest increasing or decreasing? Hepion Pharmaceuticals saw a decrease in short interest in July. As of July 31st, there was short interest totaling 8,200 shares, a decrease of 49.4% from the previous total of 16,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Hepion Pharmaceuticals' short interest compare to its competitors? 0.12% of Hepion Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Hepion Pharmaceuticals: Entero Therapeutics, Inc. (6.39%), PMGC Holdings Inc. (7.84%), Enveric Biosciences, Inc. (11.92%), PainReform Ltd. (7.21%), Lipella Pharmaceuticals Inc. (0.10%), SciSparc Ltd. (2.53%), Galmed Pharmaceuticals Ltd. (2.11%), Can-Fite BioPharma Ltd. (10.13%), CNS Pharmaceuticals, Inc. (7.71%), Aditxt, Inc. (5.07%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Hepion Pharmaceuticals stock? Short selling HEPA is an investing strategy that aims to generate trading profit from Hepion Pharmaceuticals as its price is falling. HEPA shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Hepion Pharmaceuticals? A short squeeze for Hepion Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of HEPA, which in turn drives the price of the stock up even further. How often is Hepion Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HEPA, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies ENTO Short Interest Data ELAB Short Interest Data ENVB Short Interest Data PRFX Short Interest Data LIPO Short Interest Data SPRC Short Interest Data GLMD Short Interest Data CANF Short Interest Data CNSP Short Interest Data ADTX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:HEPA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access